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Bronchopulmonary dysplasia (BPD) is a chronic inflammatory lung disease of very-low-
birth-weight (VLBW) preterm infants, associated with arrested lung development and a 
need for supplemental oxygen. Over the past few decades, the incidence of BPD has 
significantly raised as a result of improved survival of VLBW infants requiring mechanical 
ventilation. While early disease detection is critical to prevent chronic lung remodeling 
and complications later in life, BPD is often difficult to diagnose and prevent due to the 
lack of good biomarkers for identification of infants at risk, and overlapping symptoms 
with other diseases, such as pulmonary hypertension (PH). Due to the current lack of 
effective treatment available for BPD and PH, research is currently focused on primary 
prevention strategies, and identification of biomarkers for early diagnosis, that could also 
represent potential therapeutic targets. In addition, novel histopathological, biochemical, 
and molecular factors have been identified in the lung tissue and in biological fluids of 
BPD and PH patients that could associate with the disease phenotype. In this review, we 
provide an overview of biomarkers for pediatric BPD and PH that have been identified 
in clinical studies using various biological fluids. We also present a brief summary of 
the information available on current strategies and guidelines to prevent and diagnose 
BPD and PH, as well as their pathophysiology, risk factors, and experimental therapies 
currently available.
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iNTRODUCTiON
Bronchopulmonary dysplasia (BPD) is a chronic inflammatory lung disease associated with arrested 
pulmonary development and a need for supplemental oxygen. According to the 2001 NIH Consensus 
Group, the clinical definition of BPD includes requirement of ventilatory support and supplemental 
oxygen at 36-week postmenstrual age (PMA) (1). Although the cause of the disease is multifactorial 
and includes both genetic and environmental factors, the mechanisms associated with the disease 
pathogenesis are not completely understood (2).
The incidence of BPD corresponds to 10,000 premature infants in the United States annually (3). 
The affected infants often have prolonged and recurrent hospitalizations that can lead to lifelong 
alterations in lung function, compromising their quality of life (3). The long-term consequences of 
BPD have been described in a variety of studies, and include altered pulmonary function, increased 
susceptibility to infection, and increased incidence of inflammatory lung disease and airway 
hyper-reactivity. In addition, approximately 40% of pediatric BPD patients develop pulmonary 
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hypertension (PH), a serious debilitating disease associated with 
progressive elevation of pulmonary artery pressure that can lead 
to right ventricular failure and death (4).
In the recent years, PH has been associated with significant 
morbidity and mortality in infants with BPD (5, 6). A recent ret-
rospective cohort study on PH patients indicated that the disease 
still presents with high morbidity, mortality, and cost of treatment 
(7). However, diagnostic biomarkers for predicting disease risk 
and standardized clinical criteria for PH diagnosis are lacking, 
there are currently not enough studies focusing on neonatal 
PH associated with BPD. Thus, it is important to continue to 
investigate the mechanisms underlying the pathogenesis of PH, 
and in particular, of BPD-associated PH, in search for alternatives 
that will allow for better therapeutic management and prevention 
strategies.
PATHOPHYSiOLOGY OF BPD AND PH
To have a clear understanding of the pathophysiology of BPD, it 
is necessary to understand the normal lung development and the 
molecular pathways associated with the disease. Five stages have 
been identified in lung development: embryonic, pseudoglandu-
lar, canalicular, saccular, and alveolar (Figure 1). The first stage, 
named embryonic stage (4–7 weeks gestation), begins with the 
formation of a lung bud that emerges from the ventral foregut 
and posterior division to form two buds that lie on either side of 
the future esophagus. Successive branching within the expanding 
mesenchyme continues to form lobar and segmental airways in 
each lung. At the end of the embryonic stage, a network of nerves 
and ganglia are developed along with the smooth muscle to form 
the airways. These nerves and ganglia increased in size at 16 to 
18 weeks gestation (8). Both the smooth muscle and mesenchy-
mal cells secrete neurotrophic factors involved in both nerve 
growth and extension into the airways (9, 10). Next, during the 
pseudoglandular stage (7–17 weeks gestation), further division of 
the airway buds occurs, and there is a continuous differentiation 
of epithelial cells to form adult structures of cartilage, vascular 
networks, submucosal glands, and bronchial smooth muscle. At 
the following stage, the canalicular stage (17–27 weeks gestation), 
branching continues and respiratory airways form. In order to 
form the blood gas barrier, the epithelium starts thinning and 
becomes surrounded by a network of capillaries. Differentiation 
of the epithelial cells into type I and II pneumocytes occurs, 
and type II cells begin to produce surfactant. In this stage, sex 
differences begin to appear, with the female lung developing 
faster than the male lung, resulting in increased risk for BPD in 
prematurely born males than females (11, 12). In the saccular 
stage (24–36 weeks gestation) surfactant maturation continues, 
and the connective tissue forms thin septa within the airspaces 
containing a double pulmonary capillary layer (13, 14). Finally, 
in the alveolar stage, new tissue ridges lift off the existing primary 
septa and extend into the airspaces, where they subdivide the sacs 
into smaller alveoli (secondary septation) (15). This final stage 
begins at 36 weeks gestation and remains throughout infancy and 
adolescence.
The definition of BPD has evolved throughout the years (16). 
The “old BPD” definition was associated with the requirement 
of elevated oxygen levels and time spent on ventilatory support, 
which induced injury on an immature and surfactant deficient 
lung (17). This resulted in lung histopathological changes, damage 
of the airway epithelium, smooth muscle hyperplasia with areas 
of over inflation, atelectasis, fibrosis, and vascular hypertension 
(18). However, this definition has changed over time due to the 
utilization of antenatal steroids, aggressive medical interventions, 
and neonatal ventilation strategies that led to increased survival 
of extremely preterm infants. As a result, the “new” BPD is not 
primarily defined by increased ventilation and oxidant injury, 
but rather by the arrest of lung development (16). The lungs 
have some inflammation with accompanying pro-inflammatory 
cytokine response and fibrosis, but the saccular spaces show 
incomplete alveolar and vascular development (16, 19). Animal 
models including mechanically ventilated preterm baboons that 
developed BPD have shown arrest of alveolarization, decrease in 
the number of alveoli, and enlargement of airspaces that caused a 
reduction in the total lung internal surface (20).
Preterm and very-low-birth-weight (VLBW) infants have 
a higher risk of BPD because their lung development is often 
interrupted at the saccular and alveolar stages (3) (Figure  1). 
Therefore, these infants begin early pulmonary gas exchange with 
an inefficient alveolar and capillary network. In addition, multiple 
antenatal and postnatal factors, including infection, hyperoxia, 
and barotrauma can also contribute to the disease development, 
and can lead to the release of inflammatory cytokines that activate 
cell death pathways in the lung (21). Thus, BPD is the result of 
the healing and repair of lung damage that leads to fewer and 
larger alveoli, and a dysmorphic pulmonary vasculature (22). 
Furthermore, preterm infants are more vulnerable to oxidative 
stress due to their lack of adequate antioxidant protection, and 
their inability to induce antioxidant defenses while receiving 
supplementary oxygen (23). Pro-inflammatory cytokines are 
released in response to infection, but also in conditions of spe-
cific inflammation associated with mechanical ventilation (24). 
Inflammatory placental disorders and chorioamnionitis are also 
associated with BPD development due to coexistence of oxidative 
stress (25, 26).
It is still controversial whether BPD results in a decrease (27), 
or an increase (28) in pulmonary microvasculature. Studies 
in animal models and human tissue have shown alterations in 
both number and distribution of vessels in the distal lung (29). 
Studies in autopsies of infants who died from BPD have shown a 
decrease in the expression of the endothelial cell marker platelet/
endothelial cell adhesion molecule-1 (PECAM-1), and vascular 
endothelial growth factor (VEGF), which are related to the 
dysmorphic and abnormal distribution of alveolar capillaries in 
thickened alveolar septa (14, 30). By contrast, high PECAM-1 
levels were also observed in lungs of infants who died from BPD 
after being long-term ventilated, and associated with an increase 
in volume of air exchanging parenchyma and microvascular 
endothelial volume, but an immature microvasculature that 
resembled a saccular architectural pattern (31). Studies in mice 
also showed that the mRNA levels of VEGF (a known angiogenic 
factor) are significantly increased in type II pneumocytes during 
alveolar development. By contrast, VEGF absence in knockout 
mice resulted in delayed alveolarization and reduced capillary 
FiGURe 1 | embryonic and fetal lung development and bronchopulmonary dysplasia (BPD): five stages are identified in human fetal lung 
development that can be affected by both antenatal and postnatal factors, resulting in increased susceptibility to develop BPD. Preterm infants born 
at the canalicular or saccular stages have incomplete lung development and high risk for BPD. However, not all preterm infants develop BPD, indicating that other 
factors can contribute to the disease development, and the disease could be preventable. A summary of risk factors and potential prevention and management 
strategies is presented in the diagram.
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FiGURe 2 | Pathophysiology of pulmonary hypertension (PH) secondary to bronchopulmonary dysplasia (BPD). A combination of antenatal and postnatal 
factors leads to the development of bronchopulmonary dysplasia (BPD). Disruption of vascular growth is caused by hypoxemia and vascular remodeling with 
posterior increase of vascular resistance. These changes lead to pulmonary vascular disease with increases vasoreactivity, vascular tone, and pulmonary vascular 
resistance. Thus, development of PH is a multifactorial consequence of BPD, which results in hemodynamic instability and long-lasting health consequences.
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number in mouse lungs (32). Other reports have shown that low 
oxygen tension promotes growth and function of pulmonary 
artery endothelial cells during normal fetal lung development. In 
this regard, nitric oxide (NO) seems to play a critical role in the 
modulation of lung angiogenesis; thus, an impaired endothelial 
NO production may contribute to the abnormal lung vascular 
development seen in infants with BPD (33). On the other hand, 
angiotensin-converting enzyme (ACE) has been found in fetal 
tissue of human lungs as early as 12  weeks of gestation, with 
an increase of its levels throughout gestation and postnatally. 
However, ACE was downregulated in lung tissue from autopsies of 
infants who died from BPD, suggesting that ACE may be involved 
in the pathophysiology of BPD (34). Therefore, regardless of the 
definition, common findings (vascular remodeling, increased 
vascular tone, altered vasoreactivity, and decreased vascular 
surface area) are observed in patients diagnosed by the “new” and 
“old” BPD definitions, and both result in increased pulmonary 
vascular resistance and PH that can lead to right ventricular 
hypertrophy and dysfunction (4). Thus, abnormal vascular 
development in BPD leads to a decrease in the alveolar capillary 
surface area with inefficient gas exchange; which increases not 
only the need of prolonged ventilatory support, susceptibility 
for hypoxemia, and acute respiratory infections, but also to an 
increase in the risk of developing severe PH (35). Moreover, 
PH contributes to abnormal cardiopulmonary physiology with 
poor function of right ventricle (RV), impaired cardiac output, 
limited oxygen delivery, increased pulmonary edema, and risk of 
sudden death (35). Cardiac catheterization studies have revealed 
an abnormal pulmonary vascular physiology with abnormal 
vasoreactivity and elevated pulmonary vascular resistance such 
that even mild hypoxia results in marked elevation of pulmonary 
vascular pressures (35–37).
A complex signaling between the developing lung epithelium 
and the adjacent vascular endothelium results in normal develop-
ment of lung vasculature. These signaling pathways involve mol-
ecules, such as VEGF and endothelial nitric oxide (eNO), which 
in animal models have been found to increase progressively dur-
ing pulmonary vascular growth in the last half of gestation (38). 
Other preliminary studies have demonstrated a pharmacological 
inhibition of VEGF receptors that leads to attenuation of vascular 
growth and abnormal vasodilator capacity of pulmonary blood 
vessels (39, 40). This increased pulmonary vascular vasoreactivity 
leads to increased overall vascular resistance that is exaggerated 
even with minor left to right shunt of blood via patent ductus 
arteriosus (PDA), cardiac (patent foramen ovale, arterial receptor 
defect, ventricular septal defect) or intrapulmonary arteriovenous 
pulmonary vessels that results in a marked vasoconstrictor 
response and greater hemodynamic instability (Figure 2).
CLiNiCAL CLASSiFiCATiON OF  
BPD AND PH
According to the National Institute of Child Health and Human 
Development (NICHD) and National Heart, Lung, and Blood 
Institute (NHLBI) Workshop criteria, BPD is defined in three 
levels of severity, according to gestational age (GA) and oxygen 
requirement of preterm infants. Mild BPD is defined as requiring 
at least 28 days of supplemental oxygen therapy plus discharge or 
termination of supplemental oxygen therapy by 36 weeks PMA 
(infants <32 weeks GA), or by 56 days postnatal age or discharge 
(infants ≥32 weeks GA). Moderate BPD is defined as requiring at 
least 28 days of supplemental oxygen therapy with less than 30% 
of oxygen at 36 week PMA (infants <32 weeks GA) and at 56 days 
TABLe 1 | Comparison of pediatric pulmonary hypertension classification 
systems.
wHO clinical classification 
system
Panama classification system
Understanding of congenital 
heart disease in adult survivors
Based on clinical practice
Not intended to be used as a therapeutic guide
Does not include 
perinatal maladaptation, 
maldevelopment, and 
pulmonary hypoplasia as 
causative factors in neonatal 
pulmonary hypertension
Emphasizes concepts of prenatal and 
perinatal maladaptation, maldevelopment, and 
pulmonary hypoplasia
Unique to pediatric disorders (neonates to 
adolescents)
Gives importance to chromosomal and genetic 
syndromes
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postnatal age or discharge (infants ≥32 weeks GA). Finally, severe 
BPD is defined as requiring at least 28  days of supplemental 
oxygen therapy with 30% of oxygen, greater or positive pressure 
at 36 weeks PMA or at discharge (for infants <32 weeks GA), 
and at 56 days postnatal age or discharge (for infants ≥32 weeks 
GA) (1).
The clinical diagnosis of pediatric PH can be done by two 
different definitions: the WHO and the Evian classifications. We 
have summarized the major differences between the two classifi-
cation systems in Table 1. In the WHO categorization, the criteria 
used for pediatrics PH are similar to that of adult PH and includes 
multiple factors (41). By contrast, the Evian Classification catego-
rizes PH into five classes: (1) pulmonary arterial hypertension, (2) 
PH due to left heart disease, (3) PH associated with pulmonary 
diseases/chronic hypoxemia, (4) chronic thromboembolic PH, 
and (5) PH with unclear multifactorial mechanisms (42, 43). 
This classification has contributed to the understanding of the 
disease pathophysiology, treatment, and long-term consequences 
for adult patients. Nevertheless, exclusive disorders presented in 
early childhood are not included or defined, which represents 
a concern for the management of clinical strategies in infants. 
As a result, the pulmonary vascular research institute (PVRI) in 
Panama considered specific points for the pediatric population, 
and classified the disease into 10 categories that help understand 
aspects of the impaired structural and functional adaptation that 
occurs during transition from fetal to neonatal circulation, as well 
as their association with prenatal, perinatal, and chromosomal 
influences (44). However, although the PVRI Panama classifica-
tion has a multifactorial and clinical approach that focuses on the 
understanding of the disease and improvement of its diagnosis, 
more studies are needed before it could be used in the clinic, and 
the WHO classification continues to be preferred (35).
RiSK FACTORS
Although BPD and PH have similar risk factors, including 
extremely low GA at birth, oligohydramnios, duration of mechani-
cal ventilation, excessive oxygen therapy, and infection (45–48), 
the two diseases do not always present together. Moreover, there 
is no clear association of BPD severity with PH susceptibility, 
since clinical reports show that some infants with severe BPD do 
not develop PH, whereas others with mild BPD develop PH (48, 
49). Histopathological analyses have demonstrated that placental 
maternal vascular underperfusion (MVU) in high-risk pregnan-
cies has also been associated with increased risk of BPD and PH 
(50). Recently, a study conducted in a sheep model of chronic 
fetal hypoxia showed that fetal stressors (in  utero hypoxia and 
ischemia) can affect pulmonary vascular growth, and can lead to 
uteroplacental insufficiency, and perhaps contribute the BPD and 
PH development (51). Preeclampsia has been recognized as a risk 
factor for BPD, and rat experimental models of BPD have identi-
fied possible mechanisms associated with this increased risk. For 
example, overproduction of soluble VEGF receptor-1 (VEGFR-1, 
also known as sFlt-1), which antagonizes VEGF reducing its free 
circulating levels, seems to play a role in the development of 
BPD in newborns of mothers who suffer from preeclampsia. An 
increase in sFlt-1 in amniotic fluid has been associated with an 
impairment of alveolarization and pulmonary vascular growth, 
as well as biventricular hypertrophy in newborns, which suggests 
pulmonary and systemic hypertension (52). Furthermore, sex 
differences in lung development have been reported, and indi-
cated that the developmental transcriptome differs in the lungs of 
males and females (11). In early development [i.e., before 96 days 
post conception (dpc)], the male lung is more mature than the 
female lung, but in late development (after 96 dpc), the male lung 
is less mature compared to the female lung (Figure  1). These 
differences do not seem to affect early fetal lung development, or 
impact BPD susceptibility at earlier times (53). However, later in 
lung development, females appear to be protected for a number of 
conditions, due to the production of estrogens, which modulate 
VEGF and platelet-derived growth factor (PDGF) expression 
(54). Therefore, males are more affected by extreme prematurity 
and associated morbidities (55). Experimental studies in mice 
suggest that the protection of estrogens remains until puberty, and 
studies in mice treated with estrogens showed a higher expression 
of anti-inflammatory factors and less risk of asthma development 
(56). Nevertheless, circulating estrogen levels appear to be associ-
ated with increased risk of PH in women adults. Recently, a study 
found high levels of estradiol and higher estradiol/testosterone 
ratio, as well as low DHEA (dehydroepiandrosterone) levels to be 
associated with an increased risk to develop PH development in 
men, indicating an abnormal increase of aromatization in men 
with PH (57).
On the other hand, studies focusing on the pathology of BPD 
have centralized research efforts toward genetic studies, identifi-
cation of pathways of immunity, inflammation, and antioxidant 
defenses, mechanisms of vascular and lung remodeling, and 
surfactant protein biology (58). In this regard, genetic variants 
of surfactant proteins have been largely associated with risk for 
neonatal disease (59). A variant of the SP-A1gene (6A6) was iden-
tified as a risk factor for BPD in a German population, and two 
single-nucleotide polymorphisms (SNPs) in the SP-A2 and SP-D 
genes (1A2-rs2243639; 1A2-rs721917-rs2243639) were found as 
protective factors for BPD in a Greek population (59). Finally, 
studies aimed to predict the risk of BPD or death in preterm 
infants evaluated the score for neonatal acute physiology (SNAP). 
The SNAP is a physiological severity index for neonatal intensive 
care, based on 28 clinical items measured during the first 24 h of 
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life. A high SNAP score was found associated with development 
of BPD or death in critical ill preterm neonates (60).
SCReeNiNG AND DiAGNOSiS OF BPD 
AND BPD-ASSOCiATeD PH
Due to the high incidence of PH in BPD patients, and its high 
mortality rate, it is important to identify novel methods to 
improve early detection of PH, so that timely preventive inter-
ventions and treatment that is more aggressive can be initiated 
to improve survival. The available strategies for disease manage-
ment and prevention include controlled respiratory support, 
cardiac medications, vasodilators, and surgical or interventional 
cardiac catheterization procedures (35). The diagnosis of PH 
can be very difficult because most of its symptoms overlap with 
those of BPD (4). According to the most recent guidelines from 
the American Heart Association and the American Thoracic 
Society, echocardiograms must be performed in preterm infants 
with severe respiratory distress syndrome (RDS) undergoing 
mechanical ventilation, as well as in infants without improvement 
of RDS symptoms (35). Furthermore, patients who are diagnosed 
with moderate or severe BPD at 36 weeks of GA should be indi-
cated echocardiogram screening for PH. Electrocardiogram is 
not recommended as screening of PH because it has very low 
sensitivity. Additionally, catheterization is also recommended in 
patients diagnosed with PH and BPD, especially if severe cardi-
orespiratory symptoms persist despite optimal management, or 
long-term PH pharmacotherapy (35).
LONG-TeRM CONSeQUeNCeS  
OF BPD AND PH ON LUNG HeALTH
Various clinical studies have explored the long-term conse-
quences of BPD, particularly in adult patients with respiratory 
comorbidities. Some of these long-term consequences were 
evaluated in a study of patients born with BPD, RDS, preterm 
patients with no neonatal lung disease, and healthy patients 
born at term. The results of this study showed that patients born 
with BPD had worse pulmonary function and physical activity 
scores than patients in the other groups. These patients presented 
airflow obstruction, more gas trapping, decreased diffusion 
capacity, and evidence of bronchial hyper-reactivity when chal-
lenged with the methacholine test (61). Another study evaluated 
the metabolomic profile in exhaled breath condensates (EBC) of 
20 adolescents with history of BPD and 15 healthy adolescents 
(controls). The results showed alteration of the lipid profile in 
EBCs from BPD survivors. One of the metabolites identified 
was lysophosphatidylcholine, an oxidized phospholipid known 
to induce superoxide production in neutrophils and platelet-
activating factor (PAF) during inflammation. In addition, the 
investigators found abnormal levels of unsaturated phosphati-
dylserine, plasmenyl-phosphatidylserine, and surfactant phos-
pholipids in the BPD survivors group, indicating that the lungs 
of these patients keep long-term metabolic abnormalities that 
conduce to inflammation and hyper-reactivity (62). On the other 
hand, studies in mouse pups exposed to hyperoxia demonstrated 
structural changes during lung development that affected their 
postnatal lung function, with more effects in males than in 
females. Furthermore, these mice showed increased susceptibil-
ity to viral infections, especially to influenza A virus that led to 
higher mortality and production of lung collagen (63).
BiOMARKeRS
As mentioned above, BPD is a multifactorial disease that remains 
a significant cause of mortality and morbidity in the preterm 
infant. Several studies conducted in patients and animals have 
identified a variety of biomarkers for BPD susceptibility that 
bear the potential to make early diagnosis and allow prevention 
of the disease progression, avoiding or decreasing its effects and 
sequelae in children and adults. To this date, biomarkers have 
been detected in several biofluids, including blood, urine, serum, 
tracheal aspirates, and lung lavage. This information, combined 
with data obtained from genetic and epigenetic studies, will con-
tribute to the development of more effective diagnostic tools, to 
the discovery of molecular pathways associated with the disease 
development and progression, and to the identification of novel 
therapeutic targets. In the sections below, we have summarized 
the main findings of clinical studies conducted to seek biomark-
ers for BPD in various biological fluids.
Biomarkers for BPD
Biomarkers in Blood
As indicated in Table 2, the vast majority of biomarkers identi-
fied in blood are of protein nature, and these represent molecules 
associated with immunity, inflammation, and oxidative stress. 
We have reviewed the literature to find studies identifying these 
biomarkers in various populations, and we have compared the 
available information on patient sample size, disease phenotype, 
classification criteria, sensitivity, specificity, and predictive value 
of each biomarker. In the sections below, we have grouped this 
information by biomarker or groups of biomarkers, in order to 
facilitate comparisons among studies.
KL-6, CC16, and NGAL
A systematic review of more than 500 articles identified nine stud-
ies that proposed serum Krebs von den Lungen (KL-6), Clara cell 
secretory protein (CC16), and neutrophil gelatinase-associated 
lipocalin (NGAL) as extremely good predictors for early BPD 
diagnosis (90).
Krebs von den Lungen, also known as MUC1, is a glycoprotein 
preferentially expressed and secreted by type II pneumocytes and 
bronchial epithelial cells, whose expression has been correlated 
with the presence and severity of several lung diseases (91, 92). 
In a prospective study, cord blood (CB) and plasma KL-6 were 
identified as potential biomarkers for BPD. The study included 
135 preterm infants with a GA <32  weeks; divided into two 
groups: GA < 28 weeks (n = 42) and GA > 28 weeks (n = 93). 
Plasma KL-6 levels of at least 199 U/mL at 1 week of life, or 232 U/
mL at 2 weeks of life were excellent predictors of moderate/severe 
BPD at <28 weeks GA (Table 2) (65).
Clara cell secretory protein, also known as CC10 or CCSP, is 
a protein secreted by the tracheobronchial epithelium that has 
TABLe 2 | Biomarkers for BPD and PH.
Disease Biomarker(s) Specificity (%) Sensitivity (%) p-value AUC Reference
BPD CC16 82.6 85.7 <0.01 0.913 (64)
BPD KL-6 (1 week) 87 79 <0.05 0.8307 (65)
BPD KL-6 (2 weeks) 82 84 <0.05 0.8995 (65)
BPD NGAL 85 94 <0.01 0.91 (66)
BPD ETCO 92 80 0.05 0.96 (67)
BPD ETCO 75 97 <0.01 0.97 (68)
CLD ETCO 72 100 <0.05 0.87 (69)
BPD CO-Hb 75 88.9 0.002 0.882 (70)
BPD suPAR 84.6 88 <0.001 0.902 (71)
BPD AFP – – – – (72)
BPD hCG – – – – (72)
BPD uE3 – – – – (72)
BPD MMP-9 – – 0.057 – (73)
BPD IL-6 86 51 0.003 0.849 (73)
BPD gp130 82 51 0.048 – (73)
BPD PLGF 95 53 <0.001 – (74)
BPD Endostatin – – 0.029 – (75)
BPD NT-pro-BNP – – 0.006 – (76)
BPD BNP 85.7 76.1 0.028 0.8 (77)
BPD rs3771150 (IL-18RAP) – – 0.012 – (78)
BPD rs3771171 (IL-18R1) – – 0.07 – (78)
BPD rs1245560 (SPOCK2) – – – – (79)
BPD rs1049269 (SPOCK2) – – – – (79)
BPD miR-133b, miR-7, miR-152, and 
miR-30a-3p
80 87 <0.01 0.91 (80)
BPD miR-206 – – <0.01 – (81)
BPD miR-219 – – – – (82)
BPD F2-isoprostane – – 0.53 (83)
BPD 8-OHdG (day 3) 62.9 82.4 0.037 0.037 (84)
BPD 8-OHdG (day 7) 61 85.7 0.02 0.770 (84)
BPD β-2-microglobulin 83 73 0.0001 0.800 (85)
BPD myoinositol – – – – (86)
BPD lactate – – – – (86)
BPD taurine – – – – (86)
BPD TMAO – – – – (86)
“New” BPD IL-6 – – 0.11 – (87)
“New” BPD IL-8 – – 0.25 – (87)
“New” BPD IL-10 – – 0.15 – (87)
“New” BPD PDGF – – 0.42 – (87)
“New” BPD VEGF – – 0.67 – (87)
“New” BPD TGF 0.38 – (87)
“New” BPD MCP – – 0.93 – (87)
BPD-PH ADMA – – 0.02 – (88)
BPD-PH rs2781666 (arginase I) – – 0.047 – (89)
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been identified as a marker for lung epithelial injury (93). A 
study comparing blood CC16 levels in mechanically ventilated 
neonates identified higher CC16 serum concentrations in infants 
who developed BPD as early as 2  h after birth (64). Elevated 
serum levels of CC16 at 72 h after birth were highly predictive of 
BPD development (Table 2).
Neutrophil gelatinase-associated lipocalin, also known as 
lipocalin-2, is a glycoprotein expressed by granulocytes whose 
expression has been found associated with respiratory and 
inflammatory disease (94). In a study of 36 preterm infants, 
serum NGAL levels of ≥82 ng/mL at birth were predictors of BPD 
in patients with GA < 31 weeks (66).
ETCO and CO
A number of studies have assessed end tidal carbon monoxide 
(ETCO) as a good biomarker for BPD (67, 90). Sequential ETCO 
measurements in a population of preterm infants (n = 50) born 
at GA < 32 weeks revealed higher ETCO levels in infants who 
develop BPD (n = 14). ETCO levels of >2.15 ppm at day 14 after 
birth were potential predictors of BPD (Table 2) (67). A second 
study by the same group evaluated 78 preterm infants with 
GA < 33 weeks, classified into mild BPD (n = 12), moderate BPD 
(n = 15), severe BPD (n = 12), and no BPD (n = 39). ETCO at day 
14 was a good predictor of BPD with high sensitivity and specific-
ity (68) (Table 2). Another study evaluated associations of ETCO 
levels with severity of RDS and chronic lung disease (CLD), and 
found that infants with RDS had significantly higher ETCO levels 
during the first week of life than controls (69). Moreover, infants 
who developed CLD had higher ETCO levels (>2.5 ppm) during 
the first 12 h of life than those without CLD (Table 2).
Since carbon monoxide (CO) is produced endogenously 
during oxidative stress processes and pro-inflammatory cytokine 
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release (95, 96); a study assessed the potential of plasma CO as 
a biomarker for BPD using carboxyhemoglobin (CO-Hb) as 
a measure of CO in the blood. This study identified significantly 
higher CO-Hb plasma levels in infants with moderate/severe 
BPD vs. no/mild BPD (n =  25) (Table  2), and concluded that 
CO-Hb could be used as a biomarker of oxidative damage and 
inflammation in the lung of preterm infants (70).
sST2, IL-33, and suPAR
A group of investigators studied the potential of three soluble 
biomarkers for BPD prediction in umbilical CB and in periph-
eral blood (PB): soluble ST2 (sST2), interleukin 33 (IL-33), and 
soluble urokinase plasminogen activator receptor (suPAR). The 
ST2 gene produces a soluble secreted form (sST2) and a trans-
membrane form (ST2L) of the IL-1 receptor in Th2 cells, mast 
cells, and macrophages (97). Interleukin 33 (IL-33) is a member 
of IL-1 cytokine family and a modulator of inflammation in the 
pathogenesis of chronic diseases (98). The urokinase plasmino-
gen activator (uPA) and its receptor (uPAR) are expressed in 
endothelial and immune cells and participate in the regulation 
of cell migration, angiogenesis, proliferation, and adhesion. 
A soluble form of uPAR (suPAR) can be found and measured in 
body fluids, such as plasma and urine (99). The study evaluated 
concentrations of IL-33, sST2, and suPAR in a cohort of 38 pre-
term infants (GA ≤ 32 weeks) with and without BPD, and found 
significantly higher levels of PB-suPAR and PB-sST2 in BPD 
patients (Table 2), but no significant CB levels of these markers. 
Patients with PB-suPAR levels >1.55 ng/mL had higher risk for 
BPD development (71).
IL-6, IL-6R, gp130, and MMP-9
An independent study conducted in CB from 134 premature 
infants evaluated the potential of interleukin-6 (IL-6), its receptor 
IL-6R, soluble gp130, and matrix metalloproteinase 9 (MMP-9) 
as biomarkers of BPD. IL-6 is a cytokine involved in inflamma-
tion, immune regulation, hematopoiesis, and oncogenesis (100). 
IL-6 binds to IL-6R, which associates with the signal transducing 
membrane protein gp130 (a molecule that has a membrane and 
a soluble form), with a consecutive activation of downstream 
signaling cascades that result in gene expression regulation (101–
103). MMP-9 acts as a defense factor against lung damage and 
inflammation in animal models (104). The study found increased 
levels of these biomarkers in the BPD group, with higher levels 
of IL-6 and soluble gp130 correlating with highest risk for BPD 
(Table 2). Levels of IL-6 of 46.125 pg/mL were good predictors of 
BPD in infants with GA < 28.5 weeks (73). However, a separate 
study comparing serum of patients diagnosed with the “old” 
vs. “new” BPD definition found increased levels of profibrotic/
angiogenic factors [transforming growth factor-beta1 (TGFβ-1); 
PDGF BB fraction, PDGF-BB, and VEGF] and decreased levels of 
IL-6 in “new BPD” patients, but no differences in the “old BPD” 
patients (87).
VEGF, PLGF, and BNP
We mentioned earlier that VEGF plays an important role in alveo-
lar development, and that altered levels of VEGF could constitute 
risk factors for BPD and PH development. A research group 
examined levels of placental growth factor (PLGF, a member of 
VEGF family involved in angiogenesis) in CB of BPD patients 
vs. controls. The study found higher levels of PLGF (>17 mg/dl) 
in CB of BPD patients (Table 2); however, the concentration of 
PLGF was also associated with the number of days on ventilator 
(74). Another biomarker related to VEGF is endostatin, which 
antagonizes the effects of VEGF and other pro-angiogenic factors 
(105). A study evaluating the concentration of endostatin in cord 
plasma of 92 preterm infants (GA < 32 weeks; BW < 1500 g) and 
48 healthy term infants (GA > 37 weeks; BW > 2500 g) found 
that endostatin concentration in VLBW infants was significantly 
lower than that in healthy term infants. However, during the 
first two postnatal weeks, the levels of endostatin were high in 
VLBW preterm infants if these were intubated and receiving high 
concentrations of oxygen. Moreover, in an independent study, 
higher endostatin levels were found in VLBW preterm infants 
who developed BPD vs. those who did not (75).
Finally, due to the association of BPD with diastolic dysfunc-
tion and impaired left ventricle myocardial performance index in 
preterm infants (106), some studies have identified a significant 
correlation of B-type natriuretic peptide (BNP) with BPD diag-
nosis. In one study conducted in infants who developed BPD at 
4  weeks of age, plasma concentrations of N-terminal pro-BNP 
(NT-pro-BNP) were significantly increased in the BPD group 
(3208  pg/dl) vs. the control group (1122  pg/dl). However, one 
problem with this study was that the levels of NT-pro-BNP were 
much higher in the control group than the levels previously 
reported in full term healthy neonates (76). In a different study, 
the potential of BNP as a biomarker for BPD severity was assessed 
in 60 premature infants (GA <  32  weeks). The study revealed 
higher plasma BNP levels in moderate and severe BPD patients 
at GA =  36 ±  2  weeks or at discharge time. As a result, BNP 
plasma levels of 24.4 pg/mL at GA = 36 weeks were proposed as 
a predictive biomarker for BPD severity (77).
Serum Biomarkers in Maternal Blood
In a large study (662,889 pregnancies), a research group exam-
ined the relationship between second-trimester maternal serum 
levels of alpha-fetoprotein (AFP), human chorionic gonadotro-
pin (hCG) and unconjugated estriol (uE3) and BPD. The results 
showed that increased levels of AFP, hCG, and uE3 were associated 
with an increased risk of BPD in the newborn. Risk for BPD was 
higher when AFP and hCG levels were above the 95th percentile 
and when uE3 levels were below the fifth percentile (72).
In summary, the vast majority of biomarkers for BPD have 
been studied in serum. The advantages of using serum are the 
availability of reference protein values for normalization, and 
the relatively high concentrations of some of the biomarkers 
identified. The disadvantages of using serum are related to chal-
lenges associate with sample collection and volumes needed, 
especially in VLBW newborns, which could explain why most 
studies were conducted in very small sample sizes. Of the protein 
biomarkers studied, the following showed very high sensitivity 
to identify infants at risk for BPD: NGAL, KL-6, IL-6, suPAR, 
and BNP. However, the most sensitive markers were PLGF and 
ETCO (Table  2). We believe that non-protein molecules [e.g., 
EtCO and microRNAs (miRNAs)] are among the most promising 
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biomarkers to be used in future studies, because of the nature of 
the techniques used for their detection and quantification (EtCO 
is measured by the use of an electrochemical sensor, and miRNAs 
can be amplified by PCR and/or RNA sequencing). Moreover, 
the diagnostic and prognostic potential of miRNAs as biomarkers 
relies mainly on their high stability even after being subjected 
to severe conditions (e.g., extreme temperatures, very low or 
high pH, extended storage, and numerous freeze–thaw cycles) 
that would normally degrade most RNAs (107). Furthermore, 
detecting specific miRNA species is generally much easier and 
accessible than detecting specific proteins (28). The development 
of more sensitive and specific antibodies for protein biomarkers 
may also favor the use of these in the clinic. A combination of 
biomarkers that are easy to obtain and measure in small amounts 
of serum will provide a useful tool for BPD diagnosis, especially 
when dealing with low sample volumes in VLBW infants.
Biomarkers in Urine
Over the past few years, the study of metabolomics (low molecular 
mass metabolites) in biological samples has been relevant in the 
process of phenotypic description of neonatal diseases (108, 109). 
A study evaluating metabolite levels in urine samples collected at 
24–36 h post birth in 36 preterm infants found increased levels 
of four metabolites: lactate, taurine, trimethylamine N oxide 
(TMAO), myoinositol, and decreased levels of gluconate in BPD 
vs. non-BPD patients. Based on these results, it was suggested that 
an increase in anaerobic respiration occurs during the course of 
BPD, as indicated by the increase in lactate. TMAO and taurine 
participate in processes of osmoregulation and membrane stabi-
lization, and taurine has known roles in detoxification, apoptosis, 
and calcium homeostasis functions. Interestingly, the investiga-
tors concluded that BPD is a congenital disease associated with 
genetic factors and intrauterine epigenetics issues (86).
One very successful biomarker evaluated in urine of BPD 
patients is β-2-microglobulin (B2M), due to its association with 
human histocompatibility antigen (HLA) in inflammatory dis-
eases (110, 111). A study conducted in 96 preterm infants found 
higher B2M urine levels in BPD patients in the first 48 h of birth, 
indicating that B2M could serve as a biomarker for BPD (85).
With oxygen toxicity as significant contributor of BPD patho-
physiology, some studies aimed to identify metabolite products 
of oxidant injury in the urine. In one study, F2-isoprostane 
(F2-IsoP), a metabolite formed by lipid peroxidation of cellu-
lar membranes, was measured in 40 preterm infants with and 
without BPD, but found no significant of F2-IsoP in the neo-
natal period (83). In another study, leukotriene E4 (LTE4) and 
8-hydroxyguanosine (8-OHdG), two oxidant injury markers, 
were evaluated in the urine of 60 preterm infants. LTE4 results 
from the degradation of cell membranes, and it has been studied 
as a severity marker of asthma (112), and 8-OHdG is a biomarker 
of DNA damage (113). The results showed increased levels of 
8-OHdG, but not LTE4, in moderate/severe BPD at day 7, and 
higher LTE4 levels in patients diagnosed with atypical BPD. 
According to these results, it was suggested that oxidative DNA 
damage is associated with the pathogenesis of classic BPD, and 
that inflammatory processes may have a more predominant role 
in atypical BPD (84).
Finally, the system of pulmonary neuroendocrine cells 
(PNEC), such as solitary cells and innervated clusters, and 
neuroepithelial bodies (NEB) produce a variety of neuropeptides 
(bombesin, calcitonin) and amines (5-HT). The role of these spe-
cialized cells is now beginning to be appreciated in normal lung 
but also in pulmonary diseases, such as BPD (114). Therefore, 
it has been proposed that the neuropeptides secreted by this 
system could potentially serve as biomarkers for neural damage 
associated with BPD. A research study conducted in premature 
baboons identified high urine levels of bombesin-like peptide 
(BLP) associated with BPD development, and suggested a role 
of BLP in mechanisms of lung injury. Furthermore, when the 
research group administered an anti-BLP blocking antibody to 
the BPD baboons, an improvement in the oxygenation index and 
a decrease of inflammatory cells were found, indicating that BLP 
could be an early biomarker for BPD and a potential therapeutic 
target (115).
In summary, urine biomarkers have the advantage of non-
invasive procurement for large amounts, and relatively high pro-
tein stability when compared to other fluids. However, urine also 
has the disadvantage of wide variability in protein concentration, 
and lack of information on premature newborn’s urine protein 
profiles that will allow for easy normalization of biomarker expres-
sion. The studies described above indicate that β-2-microglobulin 
is a promising biomarker with high sensitivity and specificity that 
can help in early detection of BPD in newborns.
Biomarkers in Bronchoalveolar Lavage Fluid
In order to better understand cellular and molecular events that 
occur locally in the lung during the course of BPD, a research 
group evaluated protein changes in bronchoalveolar lavage fluid 
(BALF) from prematurely born infants with BPD. The study 
found that patients with lower GA (23–25 weeks) had increased 
levels of annexin-3, surfactant-associated protein A2 (SFTP-A2), 
and serum proteins, such as albumin, serotransferrin, and 
clusterin. These patients also had decreased levels of calcium 
signaling-related proteins, leukocyte elastase inhibitor, chloride 
intracellular channel (CLICL1), and calcyphosine (CAPS) when 
compared to patients with higher GA (26–29 weeks). By contrast, 
BALF measurements in BPD vs. non-BPD patients revealed 
higher CAPS, and lower calcium and integrin binding protein-1 
(CIB1) levels in severe vs. mild BPD patients (116). CAPS is 
associated with the regulation of cell proliferation, cell differ-
entiation, and surfactant secretion. Calcium signaling-related 
proteins regulate epithelial differentiation and development 
of the air–blood barrier. SFTP-A2 has known regulatory roles 
in surfactant phospholipid secretion; and both SFTP-A2 and 
annexin-3 are inhibitors of phospholipase A2 (PLA2), which is 
implicated in inflammation and surfactant catabolism. Therefore, 
in BPD, CIB1 downregulation might impair calcium signaling in 
lung cells, contributing to lung dysfunction during the course of 
BPD (116).
Endothelin- 1 (ET-1) is a pro-inflammatory and potent vaso-
constrictor expressed in high concentrations in the lung. A study 
evaluated ET-1, IL-6, and IL-8 expression in tracheal aspirates 
(TAs) from preterm infants with and without BPD, at various 
time points. The levels of ET-1, IL-6, and IL-8 gradually increased 
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from days 1 to 7 of life in TAs from the BPD group, but not in 
controls. Additionally, leukocyte counts in TAs were also higher 
in the BPD group (117).
Together, these studies have identified biomarkers in lung 
fluids that are likely to be associated with local changes in gene 
expression. However, the procurement of these samples is more 
invasive, and requires the patient to be intubated, which limits its 
use and the availability of proper controls in studies. We believe 
that these molecules represent not only potential powerful dis-
ease diagnostic tools but also therapeutic targets for drugs that 
act locally in the lung.
Genetic Biomarkers
For many decades, investigators have hypothesized that BPD was 
a genetic disease. Multiple research groups performed cohort, 
twin, and familial DNA genotyping studies (59, 118–120). 
However, most studies have failed to identify genetic asso-
ciations with BPD development and/or severity. One research 
group examined DNA samples from BPD patients from differ-
ent populations (Northern Finnish, Canadian, and Hungarian) 
to compare 44 SNPs in the IL-6, IL-6R, and gp130 (IL-6ST), 
IL-10, tumor necrosis factor (TNF), and glucocorticoid recep-
tor (NR3C1) genes, but failed to identify associations with BPD 
susceptibility (121).
A recent genome-wide association study (GWAS) conducted 
in a large cohort of preterm infants (n = 1,091) evaluated the 
association between SNP and BPD. The investigators genotyped 
6,324 SNPs in 601 selected genes in patients with or without RDS 
and BPD (using the “old” BPD definition). Furthermore, the 
preterm infants were classified according to their ethnicity in 
Caucasian (CA; n = 922) and African American (AA; n = 169) 
groups, and confirmed their findings in two independent 
populations. This study identified two SNPs (rs3771150 in the 
IL-18 gene and rs3771171 in the IL-18RAP gene) associated 
with BPD development in AA patients. Because these genes are 
known mediators of interleukin-18 (IL-18) signal transduction 
pathways, the investigators postulated that IL-18 might play 
a regulatory role in BPD, probably by altering expression of 
pro-inflammatory cytokines (78). A second GWAS study in 
CA and AA patients, conducted by a different group in 418 
preterm infants identified polymorphisms in two SNPs of the 
SPOCK2 gene (rs1245560 and rs1049269) with increased risk 
for BPD (79). Finally, another study using a combination of 
GWAS and pathway-based approaches evaluated more than a 
million SNPs in 751 preterm infants with and without BPD, 
but failed to identify SNPs associated with the disease that 
had genome-wide significance. However, pathway analysis 
performed on the top close-to-significant genes and lower false 
discovery rates revealed that the miRNA-219 family (involved 
in resolution of acute inflammation), the phosphorus oxygen 
lyase activity pathway, and the CD44 gene were associated with 
BPD and/or death. The study concluded that genetic predispo-
sition to develop severe BPD might involve mutations affecting 
pathways of lung development and repair (82). Therefore, the 
development of future therapies will need to consider target-
ing these genes and pathways in a “personalized genomics” 
approach.
miRNA Biomarkers
The use of miRNAs, a recently discovered class of non-coding 
RNAs involved in gene expression regulation, as biomarkers has 
become more common in the last decade (122). This is due to 
the remarkably high stability of miRNAs in biofluids, as well 
as the low complexity of the available methods to detect and 
quantify miRNAs, such as qPCR and RNAseq. A recent study 
conducted to evaluate miRNA expression in PB obtained from 
50 preterm infants identified four miRNAs (miR-133b; miR-7; 
miR-152; and miR-30a-3p) associated with BPD (80). Another 
study found downregulation of miR-206 in mouse lung tissue of 
an experimental BPD model vs. control. This study also found 
lower blood miR-206 levels in a cohort of BPD patients vs. con-
trols. Moreover, overexpression of miR-206 in lung cells resulted 
in increased apoptosis, and decreased proliferation, migration, 
and adhesion, as well as downregulation of the fibronectin gene 
(FN1) (downregulation of this miRNA resulted in the opposite 
effect) (81).
In summary, the diagnostic and prognostic potential of 
miRNAs is related to their high stability, and easy detection by 
molecular biology approaches. A growing number of studies 
support a potential use of secreted miRNAs as biomarkers for a 
wide variety of diseases as well as predictors of drug sensitivity 
and outcome (53, 123). In diseases, such as lung cancer, detecting 
elevated expression of single miRNAs in sputum shows a higher 
sensitivity in diagnosis than sputum cytology analysis (107). 
Moreover, small sets of miRNAs have already been shown to 
enable classification of different disease states and conditions (38, 
44, 107). For example, miRNA panels can be used to distinguish 
among different types of lung carcinoma, indicating that miRNAs 
could potentially serve as robust diagnostic biomarkers of disease 
subtypes (16, 60, 116, 121). Finally, the use of miRNA as thera-
peutic tools has reached the clinical phase for various diseases, 
and continues to expand (17, 79, 118). In the particular case of 
lung disease, tissue-specific therapeutic modulation of miRNA 
activity has been achieved via inhalation in animal models (7, 
55, 75, 78). Therefore, the use of miRNAs as biomarkers for 
pediatric inflammatory lung disease may also facilitate the future 
development of individualized diagnosis and medical strategies 
for treatment.
Biomarkers for PH
As seen below, multiple biomarkers have been investigated in the 
search of an early diagnostic tool for BPD in preterm infants. 
However, only a few studies have focused in the identification of 
biomarkers for PH development in patients with BPD. Of these, 
one study evaluated plasma levels of asymmetric dimethylarginine 
(ADMA), an inhibitor of the production of NO, as a predictor of 
PH in preterm infants with BPD (88, 124). The study was con-
ducted in 118 preterm infants with BPD, of which 23 developed 
PH. In addition to ADMA, arginine, citrulline, ornithine, and 
proline levels were also analyzed. ADMA concentrations were 
higher in patients with both BPD and PH than in patients with 
BPD alone; and plasma levels of arginine, citrulline, ornithine, 
and proline did not show differences between groups. However, 
the plasma arginine to ADMA ratio was significantly low in 
patients that developed PH. The study concluded that ADMA is 
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not only a biomarker of PH in BPD patients but it also represents 
a potential therapeutic target for the disease (88). Another study 
evaluated serum levels of endostatin/Angiopoietin-1 (AP-1) 
in premature infants with severe BPD with and without PH. 
Both endostatin levels and the ratio of endostatin/AP-1 were 
significantly increased in infants with severe BPD and PH on 
day 7 of life, indicating that a high endostatin/AP-1 ratio may 
lead to abnormal angiogenesis and could serve as a biomarker 
for PH (125).
Studies have shown that NO plays an important role in the 
control of neonatal pulmonary vascular resistance. Therefore, 
genetic studies of NO pathways have evaluated associations of 
BPD and PH, by studying SNPs in genes of the l-arginine/NO 
pathway in 140 premature neonates with BPD with and without 
PH. The study identified a SNP in the arginase I gene (rs2781666) 
associated with low arginase I levels in the BPD + PH group, sug-
gesting a protection against PH development (89).
Finally, a study conducted in 277 preterm infants evaluated the 
relationship between early echocardiographic signs of pulmonary 
vascular disease with the development of BPD or PH. In this 
study, echocardiogram evaluations were performed at 7 days of 
age (early) and at 36 weeks PMA (late) to measure right ventricu-
lar systolic pressure, cardiac shunt, and ventricular septal wall 
flattening. Of the 227 infants who developed BPD, early PH was 
diagnosed in 115 infants (42%), and late PH was identified in 39 
patients (14%). The investigators concluded that echocardiogram 
at day could be used to identify preterm infants with high risk for 
BPD and PH (6).
In summary, a critical barrier in PH prevention and effective 
treatment is the lack of a good diagnostic tool to identify BPD 
patients at risk for PH. Currently, the diagnosis of PH in BPD 
patients occurs via highly invasive procedures, such as cardiac 
catheterization. As seen above, only a handful of studies have 
explored the use of alternative approaches, and the identification 
of biomarkers for PH detection and prediction in BPD patients. 
We believe that the standardization of methods for PH diagnosis 
in pediatric patients will allow the development of larger studies 
that will explore genetic, protein, and miRNA biomarkers for 
BPD-associated PH, in several biofluids. Integration of this infor-
mation will help increase the accuracy of pediatric PH diagnosis 
in BPD, and will provide new mechanistic information for the 
future development of therapeutic interventions.
BPD/PH MANAGeMeNT AND AvAiLABLe 
eXPeRiMeNTAL THeRAPieS
The first step in the management of PH in neonates with BPD 
is treatment and prevention of severe BPD. However, there 
continues to be a need to have multi-center controlled trials for 
the treatment of BPD-associated PH that can identify effective 
strategies for management and prevention. In all neonates with 
PH, congenital heart disease must be ruled out, particularly in 
the setting of persistent pulmonary hypertension of the newborn 
(PPHN). Pulmonary vein stenosis is a rare cause of PH in neonates 
and is a close differential diagnosis of PH in older preterm infants 
with BPD (126). Although pulmonary vasodilators such as iNO, 
PDE5 inhibitors (sildenafil, tadalafil), prostacyclins, bosetan, 
and CCB have been used in the treatment of PH in neonates, 
prevention of PH remains the best treatment. Unfortunately, 
the US food and drug administration (FDA) remains skeptical 
in approving some of these medications, because these classes 
of medications have narrow therapeutic indices, hence posing 
significant safety issues. “Off label” use is common practice, as 
most clinical trials are carried out in adults. Another challenge 
in the treatment of PH in neonates is the ability to clearly define 
a clinical endpoint and monitoring of clinical improvement. 
Monotherapy or combination treatment have been used, but 
their efficacy and their short- and long-term adverse effects 
are considered prior to instituting therapies for neonatal PH. 
iNO is currently approved for treatment of PPHN in neonates, 
but its use in the prevention of BPD and PH in preterm infants 
remains to be established (127, 128). Sildenafil remains a popular 
option in the treatment of BPD-associated PH due to its ease of 
administration, however, its use is off label in children, and there 
is paucity of data/evidence for its use in preterm infants with 
BPD/PH (129). Preventive strategies, such as limiting hypoxia 
and hyperoxia, reducing prolonged mechanical ventilation, and 
treatment of hemodynamically significant PDA are all important 
in the treatment/prevention of BPD. Clinicians must pay atten-
tion to the growth and nutrition of infants with BPD as lung 
growth and alveolarization continue in the first 2  years of life, 
and supporting somatic growth is very critical. Early treatment 
of intercurrent lung infections is also very important, particularly 
in infants who are intubated and receiving invasive mechanical 
ventilation. Furthermore, chronic mechanical ventilation should 
be considered in infants with severe BPD who cannot be weaned 
from non-invasive positive pressure support. In such infants, 
chronic hypoxemic episodes and impaired ventilation together 
contribute to impaired lung growth and increasing their risks to 
developing PH. Finally, a fine balance should also be maintained 
between hypoxemia and hyperoxia; hence, oxygen-saturation 
target is monitored carefully in older preterm infants with BPD. 
Hyperoxia potentially can lead to increased oxygen free radicals 
that can contribute to lung injury.
Animal experimental models have explored the use of mesen-
chymal stem cells (MSCs) in the treatment of BPD. Studies show 
that MSCs therapy has paracrine effects with anti-inflammatory 
and antifibrotic properties that help reduce BPD, by induc-
ing vascular and alveolar growth, and inhibiting lung fibrosis 
(130). Furthermore, in studies performed on neonatal rats, BPD 
induced by hyperoxia decreased circulating and resident MSCs 
in the lung (131). Overall, the available literature indicates that 
more research is needed on stem cell therapeutic doses, long-
term effects, and safety before their use becomes available for the 
management of BPD.
DiSeASe PReveNTiON
Despite preterm and VLBW infants having a high risk of BPD, 
not all of them develop BPD. This implies that BPD could be 
prevented. According to the NHLBI workshop on the primary 
prevention of CLDs, the clue for BPD prevention is the identifica-
tion of molecular pathways that affect normal lung development 
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and lead to BPD (Figure 1). Early identification of the prenatal 
and antenatal factors that affect these molecular pathways will 
lead to timely interventions that may prevent endothelial injury 
and oxidative stress (3). Because maternal smoking has been 
associated with preterm labor and subsequently BPD develop-
ment (132), smoking cessation through counseling is one of 
strategies that can be performed in the preconception stage 
and early pregnancy. Inhaled corticoids for prevention of BPD 
have also been evaluated; however, their use is still controversial 
due to their multiple side effects (133–135). A recent study has 
reported the use of intratracheal budesonide with surfactant in 
preterm infants diagnosed with severe RDS to decrease their 
risk of developing BPD. The results showed a decrease in oxy-
gen requirement, lung injury, and pro-inflammatory cytokine 
secretion (136). The investigators used surfactant as a carrier 
in order to reach lung periphery and increase the solubility of 
budesonide; making it more effective. Furthermore, budesonide 
remained in the lung for up to 8 h when administered locally, as 
opposed to shorter times when administered systemically (137).
Several pharmacological interventions have been evaluated in 
animal models of BPD and PH in search of new molecules and 
pathways to explain the abnormal lung development in premature 
newborns with these diseases. As a result, therapeutic molecules, 
such as caffeine and other xanthine derivatives, vitamin A, and 
vitamin A analogs, were found to be effective at promoting 
lung maturation (63). Caffeine treatment has also been used 
in preterm infants to prevent apnea of prematurity, facilitate 
extubation, and decrease time on mechanical ventilation, which 
also lead to decreased BPD (107, 138, 139). However, although 
caffeine has anti-inflammatories properties, levels of caffeine 
outside of therapeutic range are associated with an increase in 
inflammation (140). In addition, a decrease in weight gain has 
been reported during the three first 3 weeks of caffeine therapy in 
preterm neonates (141). Vitamin A is another therapeutic agent 
with high evidence for prevention of BPD in extremely preterm 
infants (138) that has similar benefits to caffeine in decreasing 
duration of intubation and oxygen therapy (142).
Studies in animals have found a decrease in soluble guanylate 
cyclase (sGC) in mouse pups following hyperoxia-induced 
lung injury, indicating that activation of sGC could be used as 
a potential strategy for prevention of BPD (143). Another study 
in rats showed that sildenafil inhibition of phosphodiesterase 5 
(PDE5) resulted in increased vascular distribution in lung tissue. 
Moreover, both hypoxia-inducible factor (HIF) and VEGF levels 
were higher in lungs of BPD rats, suggesting that HIF could be 
used for management of BPD (144). Other experimental models 
of BPD have shown that vitamin D plays important roles in lung 
maturation, suggesting that vitamin D supplementation could be 
a modifiable risk factor of BPD (123). Furthermore, abnormal 
changes in alveolar development, tracheal mesenchymal dif-
ferentiation markers, and surfactant synthesis were found in the 
offspring of rats with vitamin D deficiency (145). Finally, studies 
in mice have suggested that the mother’s diet during pregnancy 
can cause placental inflammation and affect fetal lung develop-
ment. In this regard, high-fat diet during pregnancy resulted 
in alveolar simplification and a reduction of biochemical and 
structural indicators of lung maturation in mouse pups (146). 
Therefore, studies linking the composition of the mother’s diet 
during pregnancy and the development of BPD and other lung 
diseases of the newborn will warrant the use of dietary recom-
mendations as potential prevention therapies.
SUMMARY AND CONCLUSiON
Bronchopulmonary dysplasia is a multifactorial disease that 
remains the most serious lung condition of prematurity, 
and a significant cause of mortality in preterm infants. Early 
detection and diagnosis of BPD is critical to prevent disease 
progression and chronic lung remodeling. Infants with BPD 
are at increased risk for long-term hospitalization, requirement 
of oxygen supplementation after discharge, recurrent respira-
tory complications, and lifelong consequences that result from 
their impaired lung development and disturbed lung growth. 
Subclinical lung injury driven by incompletely resolved or low-
grade chronic inflammation can promote disease processes 
that manifest as fibrosis, emphysema, COPD, cancer, and inter-
stitial lung disease later in life (147, 148). In addition, between 
14 and 38% of BPD patients develop PH, a condition with over 
40% mortality that often complicates BPD (5, 6, 149, 150). 
The association of BPD with PH predisposes neonates to 
lung and cardiovascular injury, increasing susceptibility to 
infection and mortality, and affecting lung health throughout 
adulthood.
While there is currently no effective treatment for BPD, studies 
have shown that variation in ventilator settings, extubation fol-
lowed by non-invasive ventilation (e.g., nasal continuous positive 
airway pressure), together with vitamin A, caffeine, NO, and/or 
surfactant therapy may improve the outcome of BPD (151–156). 
Preventive strategies, such as minimization of feeding-related 
aspiration, optimization of nutrition, strict avoidance to tobacco 
smoke, and prevention of infection by close adherence to immu-
nization schedules have been proven to minimize lung injury, 
and help in resolution of BPD (157). Therefore, identification of 
novel less invasive early biomarkers for neonatal BPD is neces-
sary to improve detection and prognostic outcome of respiratory 
pathologies, and to initiate proper treatment that will prevent 
later complications. Moreover, development of individualized 
medicine to treat inflammatory lung disease has been hindered 
by our lack of understanding of the mechanisms responsible for 
inter-individual differences in susceptibility and severity. Thus, 
characterization of molecular events that result in altered gene 
expression during the course of lung disease is important to 
facilitate the development of individualized diagnosis and medi-
cal treatments before potentially chronic and dire downstream 
consequences become irreversible.
Although multiple studies have focused on the identification 
of genetic and epigenetic markers to predict and prevent BPD, no 
good predictive genetic markers have been reported to date. More 
recently, the search for biomarkers has been extended to biofluids, 
including blood, urine, BALF, TAs, etc., and these studies were 
successful in identifying associations of biomarkers with disease 
occurrence and severity. Although the majority of the reported 
markers are of protein nature, other molecules such as gases, 
metabolites, and miRNAs were also found associated with BPD 
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and PH. Functional and computational analyses have revealed 
that these are involved in pathways associated with immunity, 
inflammation, and oxidative stress. These biomarkers are likely 
to complement the genetic information in the identification of 
patients vulnerable to develop BPD and associated diseases, such 
as PH, and will help in the discovery of molecular mechanisms 
implicated in the disease pathophysiology.
Many of the biomarkers reported here were linked to disease 
development and/or severity, and their levels appear to depend 
on the time point in which the sample was collected, and/or 
the infant’s age. Moreover, except for some genetic studies 
conducted in large cohorts, many of the studies reported here 
were exploratory and performed in a very small number of 
patients, without validating results in an independent popula-
tion. We believe that the studies presented here have provided 
important data on biomarker expression, purification, stability, 
associations with disease, and other information necessary for 
the design of reliable predictive tools for BPD diagnosis, severity, 
and likelihood of response to therapeutics. The work performed 
over the past 15 years has provided the stepping-stone for the 
design of novel studies involving more complex techniques, 
such as next generation sequencing, and more specific and 
sensitive antibodies for the identification of biomarkers for BPD 
and PH. The generation of tools for early detection of patients at 
risk for BPD and PH will warrant the use of more aggressive and 
personalized treatment with medications, respiratory support, 
nutrition, and preventive care procedures that will improve 
disease outcomes.
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